Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Syngenta Group was the largest competitor with a 3.47% share of the market, followed by Amgen Inc with 3.29%, Monsanto (Bayer) AG with 1.48%, Illumina Inc with 1.20%, F. Hoffmann-La Roche Ltd ...

The quality and purity of the converted DNA was tested by Nanodrop. Genome-wide methylation profiling was performed using Infinium HumanMethylation 450 BeadChip array (Illumina, San Diego, CA, USA).

Illumina's 2024 results mildly exceeded preliminary results announced in January and kept its 2025 guidance for low-single-digit core sales growth and 10% adjusted earnings per share growth intact ...

AM-N and JR were involved in management of the patient. AP performed the comparative genomic hybridization array and data analysis. DB, MB, and SO performed whole exome sequencing and the data ...